The epilepsy drug market may break the 6 billion mark, and pharmaceutical companies compete for the first imitation of sodium valproate oral solution

Epilepsy (Epilepsy) is a chronic disease in which the sudden abnormal discharge of brain neurons leads to transient brain dysfunction
.
According to statistics, the in-hospital sales market for epilepsy in China has reached 4.
6 billion yuan, and the national hospital sales in the first half of this year increased by 67% year-on-year
.
It is estimated that the total sales of this market in 2021 may exceed the 6 billion yuan mark
.
Among anti-epileptic drugs, sodium valproate is an important drug, and in a sales market of 4.
6 billion yuan, sodium valproate has a market share of nearly 40%
.
It is understood that sodium valproate has a broad-spectrum antiepileptic effect.
It can treat complex partial seizures, generalized tonic-clonic seizures, myoclonic seizures and status epilepticus.
It acts on GABAA receptors and NMDA receptors, and is almost suitable for All types of epilepsy and seizures are one of the broad-spectrum anti-epileptic drugs with good effects and the first-line treatment for clinical epilepsy
.
Statistics show that in our country, more valproate dosage approved production, mainly ordinary tablets, injections, sustained release tablets, oral solutions, particles and the like
.
The author has learned that recently, new news has come in the field of sodium valproate oral solution
.
That is, the CDE website announced that Sichuan Baojiantang Pharmaceutical Co.
, Ltd.
reported the production of sodium valproate oral solution in imitation of four categories
.
This is the third company to report production of this variety
.
The other two companies are Sichuan Creed Pharmaceuticals and Hebei Renhe Yikang, but no company has passed the consistency evaluation
.
Sodium valproate oral solution is mainly used to treat general or partial epilepsy, especially the following types of seizures: absence seizures, myoclonic seizures, atonic seizures and mixed seizures, and partial epilepsy: simple or complex seizures ; Secondary generalized seizures; Special types of syndromes (West, Lennox-Gastaut)
.
With the production of Sichuan Baojiantang Sodium Valproate Oral Solution, the field of antiepileptic drugs may usher in new competitors
.
It is understood that in the field of sodium valproate, the injection market accounts for more than 60%
.
In the field of sodium valproate injection, companies applying for consistency evaluation include Fu'an Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang, and Sichuan Creed Pharmaceuticals
.
Except for Fu'an Pharmaceutical which is under review and approval, the other three companies have all been reviewed
.
In addition, Hunan Province Xiangzhong Pharmaceutical, Shan Dongfang Ming Pharmaceutical, and Shanghai Qingping Pharmaceutical submitted supplementary applications for the consistency evaluation of sodium valproate tablets, all of which have been reviewed.
Shanghai Qingping Pharmaceutical is the first to have reviewed them
.
Sodium valproate is one of the important drugs with better effects of broad-spectrum antiepileptic drugs, and this drug has a broad market development space
.
According to data, the total sales of sodium valproate in the hospital in 2020 will exceed 1.
8 billion.
In the first half of 2021, sales will increase steadily at a growth rate of 76%.
The industry said that this market share is expected to expand again
.
The antiepileptic drug market has a bright future, but the competition is also fierce
.
It is understood that in this field, in addition to sodium valproate, Levetiracetam and Occasida also occupy a very large market
.
"Although the competition is fierce, we hope to provide domestic epilepsy patients with new therapeutic drug options and bring new breakthroughs to the domestic anti-epileptic drug market
.
" The relevant person said
.